Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
294 articles
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
A Danish case-control trial uses gold-standard metabolic testing to uncover how mtDNA mutations impair muscle glucose uptake and drive insulin resistance.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
A completed OSU trial investigates whether short-term exercise training can restore impaired mitochondrial cleanup pathways in overweight and obese skeletal muscle.
Researchers test lipid, glucose, and mixed meal challenges to pinpoint optimal post-meal sample collection windows for future cardiovascular studies.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
Scientists identify an NADH-dependent molecular switch linking glycolysis to mitochondrial ATP synthesis, revealing a new metabolic control point.
A landmark 500-patient RCT finds sodium bicarbonate offers no benefit over placebo for critically ill adults with metabolic acidosis and shock.
A systematic review of 10 longitudinal studies finds elevated pancreatic fat strongly predicts future type 2 diabetes and glycemic decline.
Machine learning clusters CGM data into four distinct glycemic patterns, each linked to unique diabetic complication risks.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
